Cover Image
市場調查報告書

腎細胞癌 (RCC) :市場預測與分析

Renal cell cancer (RCC) disease forecast and market analysis to 2035

出版商 Datamonitor Healthcare 商品編碼 365186
出版日期 內容資訊 英文 283 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
腎細胞癌 (RCC) :市場預測與分析 Renal cell cancer (RCC) disease forecast and market analysis to 2035
出版日期: 2017年03月17日 內容資訊: 英文 283 Pages
簡介

本報告提供腎細胞癌治療藥市場相關調查分析,提供您市場預測,治療,流行病學,上市藥,開發平台藥物趨勢等系統性資訊。

預測:腎細胞癌

  • 摘要整理
  • 市場概要·趨勢
  • 調查手法·市場定義
  • Afinitor (everolimus)
  • AGS-003
  • Atezolizumab
  • Avastin (bevacizumab)
  • Cometriq (cabozantinib)
  • Inlyta (axitinib)
  • Lenvima (lenvatinib)
  • Nexavar (sorafenib)
  • Opdivo (nivolumab)
  • Sutent (sunitinib)
  • Torisel (temsirolimus)
  • Votrient (pazopanib)
  • 主要調查手法

治療:腎細胞癌

  • 摘要整理
  • 主要調查手法
  • 疾病定義·診斷
  • 患者區分
  • 各國治療系統
  • 目前治療選擇
  • 處方趨勢

流行病學:腎細胞癌

  • 摘要整理
  • 資訊來源·手法
  • 預測
  • 流行病學者的考察
  • 優勢與限制

上市藥:腎細胞癌

  • 摘要整理
  • 產品概要
  • 產品簡介:Afinitor
  • 產品簡介:Avastin
  • 產品簡介:Inlyta
  • 產品簡介:Nexavar
  • 產品簡介:Opdivo
  • 產品簡介:Sutent
  • 產品簡介:Torisel
  • 產品簡介:Votrient

開發平台:腎細胞癌

  • 摘要整理
  • 臨床開發平台概要
  • 最近中止的藥物
  • 標靶產品簡介
  • 臨床實驗設計
  • 腎細胞癌的治療的未來
  • 產品簡介 (後期階段) :AGS-003
  • 產品簡介 (後期階段) :Cometriq
  • 產品簡介 (後期階段) :atezolizumab

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC5807

Disease Overview

Renal cell cancer (RCC) is a tumor that originates in the renal cortex, the outer part of the kidney between the renal capsule and the renal medulla. Around 85% of all malignant kidney tumors are RCC, with other types including transitional cell carcinoma of the renal pelvis and Wilms' tumor (nephroblastoma). The incidence of RCC is higher in those over the age of 60, suggesting that the aging population may play a significant role in current and future disease burden. Datamonitor Healthcare estimates that in 2014 there were 100,290 diagnosed incident cases of RCC in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK). Over the forecast period (2014-34), this is expected to increase to 137,970 cases by 2034, representing an absolute increase of 37.6%. Overall, RCC incidence rates have been steadily increasing in both men and women in the US, Japan, and five major EU markets since the 1970s.

Table of Contents (Full Disease Coverage)

FORECAST: RENAL CELL CANCER

  • Executive Summary
  • Market Overview and Trends
  • Methodology and Market Definition
  • Afinitor (everolimus)
  • AGS-003
  • atezolizumab
  • Avastin (bevacizumab)
  • Cometriq (cabozantinib)
  • Inlyta (axitinib)
  • Lenvima (lenvatinib)
  • Nexavar (sorafenib)
  • Opdivo (nivolumab)
  • Sutent (sunitinib)
  • Torisel (temsirolimus)
  • Votrient (pazopanib)
  • Primary Research Methodology

TREATMENT: RENAL CELL CANCER

  • Executive Summary
  • Primary Research Methodology
  • Disease Definition and Diagnosis
  • Patient Segmentation
  • Country Treatment Trees
  • Current Treatment Options
  • Prescribing Trends

EPIDEMIOLOGY: RENAL CELL CARCINOMA

  • Executive Summary
  • Sources and Methodology
  • Forecast
  • Epidemiologist Insight
  • Strengths and Limitations

MARKETED DRUGS: RENAL CELL CANCER

  • Executive Summary
  • Product Overview
  • Product profile: Afinitor
  • Product profile: Avastin
  • Product profile: Inlyta
  • Product profile: Nexavar
  • Product profile: Opdivo
  • Product profile: Sutent
  • Product profile: Torisel
  • Product profile: Votrient

PIPELINE: RENAL CELL CANCER

  • Executive Summary
  • Clinical Pipeline Overview
  • Recently Discontinued Drugs
  • Target Product Profile
  • Clinical Trial Design
  • The Future of Treatment in Renal Cell Cancer
  • Product profile (late stage): AGS-003
  • Product profile (late stage): Cometriq
  • Product profile (late stage): atezolizumab

APPENDIX

  • Appendix: Marketed Drugs: Renal Cell Cancer
  • Appendix: Pipeline: Renal Cell Cancer

List of figures

  • Figure 1: RCC sales in the US, Japan, and five major EU markets, by status ($m), 2015-24
  • Figure 2: Renal cell cancer drug sales in the US, Japan, and five major EU markets, by status ($m), 2015-24
  • Figure 3: Renal cell cancer drug sales in the US, by status ($m), 2015-24
  • Figure 4: Renal cell cancer drug sales in Japan, by status ($m), 2015-24
  • Figure 5: Renal cell cancer drug sales in the five major EU markets, by status ($m), 2015-24
  • Figure 6: Patient-based forecast methodology for renal cell cancer
  • Figure 7: Price sources and calculations, by country
  • Figure 8: Afinitor sales for RCC in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Figure 9: AGS-003 sales for RCC in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Figure 10: Atezolizumab sales for RCC in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Figure 11: Avastin sales for RCC in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Figure 12: Cometriq sales for RCC in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Figure 13: Inlyta sales for RCC in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Figure 14: Lenvima sales for RCC in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Figure 15: Nexavar sales for RCC in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Figure 16: Opdivo sales for RCC in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Figure 17: Sutent sales for RCC in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Figure 18: Torisel sales for RCC in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Figure 19: Votrient sales for RCC in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Figure 20: Distribution of clear cell renal cell cancer patients across the US, Japan, and five major EU markets, by stage and country
  • Figure 21: Distribution of non-clear cell renal cell cancer patients across the US, Japan, and five major EU markets, by stage and country
  • Figure 22: Percentage of Stage I-III renal cell cancer patients receiving each type of treatment, by country
  • Figure 23: Percentage of Stage IV clear cell renal cell cancer patients receiving each treatment type at first-line, by country
  • Figure 24: Percentage of Stage IV non-clear cell renal cell cancer patients receiving each treatment type at first-line, by country
  • Figure 25: Percentage of Stage IV clear cell renal cell cancer patients receiving neoadjuvant and/or adjuvant chemotherapy, by country
  • Figure 26: Percentage of Stage IV non-clear cell renal cell cancer patients receiving neoadjuvant and/or adjuvant chemotherapy, by country
  • Figure 27: Top three regimens used in the adjuvant treatment of Stage IV clear cell renal cell cancer, by country
  • Figure 28: Top three regimens used in the adjuvant treatment of Stage IV non-clear cell renal cell cancer, by country
  • Figure 29: Top three regimens used in the neoadjuvant treatment of Stage IV clear cell renal cell cancer, by country
  • Figure 30: Top three regimens used in the neoadjuvant treatment of Stage IV non-clear cell renal cell cancer, by country
  • Figure 31: Top three regimens used in the first-line treatment of Stage IV clear cell renal cell cancer patients who do not receive surgery, by country
  • Figure 32: Top three regimens used in the first-line treatment of Stage IV non-clear cell renal cell cancer patients who do not receive surgery, by country
  • Figure 33: Percentage of Stage IV clear cell renal cell cancer patients receiving additional lines of therapy, by line of therapy and country
  • Figure 34: Percentage of Stage IV non-clear cell renal cell cancer patients receiving additional lines of therapy, by line of therapy and country
  • Figure 35: Top three regimens used in the second-line treatment of Stage IV clear cell renal cell cancer, by country
  • Figure 36: Top three regimens used in the second-line treatment of Stage IV non-clear cell renal cell cancer, by country
  • Figure 37: Top three regimens used in the third-line treatment of Stage IV clear cell renal cell cancer, by country
  • Figure 38: Top three regimens used in the third-line treatment of Stage IV non-clear cell renal cell cancer, by country
  • Figure 39: Percentage of local relapse clear cell renal cell cancer patients receiving each treatment type, by country
  • Figure 40: Percentage of local relapse non-clear cell renal cell cancer patients receiving each treatment type, by country
  • Figure 41: Top three regimens used in the first-line treatment of local relapse clear cell renal cell cancer patients who do not receive surgical treatment, by country
  • Figure 42: Top three regimens used in the first-line treatment of local relapse non-clear cell RCC patients who do not receive surgical treatment, by country
  • Figure 43: Percentage of distant relapse clear cell renal cell cancer patients receiving each treatment type, by country
  • Figure 44: Percentage of distant relapse non-clear cell renal cell cancer patients receiving each treatment type, by country
  • Figure 45: Top three regimens used in the first-line treatment of distant relapse clear cell RCC patients who do not receive surgical treatment, by country
  • Figure 46: Top three regimens used in the first-line treatment of distant relapse non-clear cell RCC patients who do not receive surgical treatment, by country
  • Figure 47: Top three regimens used in the treatment of second-line distant relapse clear cell renal cell cancer patients, by country
  • Figure 48: Top three regimens used in the treatment of second-line distant relapse non-clear cell renal cell cancer patients, by country
  • Figure 49: Top three regimens used in the treatment of third-line distant relapse clear cell renal cell cancer patients, by country
  • Figure 50: Top three regimens used in the treatment of third-line distant relapse non-clear cell renal cell cancer patients, by country
  • Figure 51: Trends in diagnosed incident cases of renal cell carcinoma in the US, Japan, and five major EU markets, by country, 2014-34
  • List of tables
  • Figure 52: Absolute growth in diagnosed incident cases of renal cell carcinoma in the US, Japan, and five major EU markets, 2014-34
  • Figure 53: Age-specific diagnosed incident cases of renal cell carcinoma in the US, Japan, and five major EU markets, by country, 2014-34
  • Figure 54: Datamonitor Healthcare's drug assessment summary of key marketed drugs for renal cell cancer
  • Figure 55: Afinitor for renal cell cancer - SWOT analysis
  • Figure 56: Datamonitor Healthcare's drug assessment summary for Afinitor in renal cell cancer
  • Figure 57: Datamonitor Healthcare's drug assessment summary for Afinitor in renal cell cancer
  • Figure 58: Avastin for renal cell cancer - SWOT analysis
  • Figure 59: Datamonitor Healthcare's drug assessment summary for Avastin in renal cell cancer
  • Figure 60: Datamonitor Healthcare's drug assessment summary for Avastin in renal cell cancer
  • Figure 61: Inlyta for renal cell cancer - SWOT analysis
  • Figure 62: Datamonitor Healthcare's drug assessment summary for Inlyta in renal cell cancer
  • Figure 63: Datamonitor Healthcare's drug assessment summary for Inlyta in renal cell cancer
  • Figure 64: Nexavar for renal cell cancer - SWOT analysis
  • Figure 65: Datamonitor Healthcare's drug assessment summary for Nexavar in renal cell cancer
  • Figure 66: Datamonitor Healthcare's drug assessment summary for Nexavar in renal cell cancer
  • Figure 67: Opdivo pivotal trial data in renal cell cancer
  • Figure 68: Opdivo for renal cell cancer - SWOT analysis
  • Figure 69: Datamonitor Healthcare's drug assessment summary for Opdivo in renal cell cancer
  • Figure 70: Datamonitor Healthcare's drug assessment summary for Opdivo in renal cell cancer
  • Figure 71: Sutent for renal cell cancer - SWOT analysis
  • Figure 72: Datamonitor Healthcare's drug assessment summary for Sutent in renal cell cancer
  • Figure 73: Datamonitor Healthcare's drug assessment summary for Sutent in renal cell cancer
  • Figure 74: Torisel for renal cell cancer - SWOT analysis
  • Figure 75: Datamonitor Healthcare's drug assessment summary for Torisel in renal cell cancer
  • Figure 76: Datamonitor Healthcare's drug assessment summary for Torisel in renal cell cancer
  • Figure 77: Votrient for renal cell cancer - SWOT analysis
  • Figure 78: Datamonitor Healthcare's drug assessment summary for Votrient in renal cell cancer
  • Figure 79: Datamonitor Healthcare's drug assessment summary for Votrient in renal cell cancer
  • Figure 80: Sutent pivotal Phase III trial data in renal cell cancer
  • Figure 81: AGS-003 for renal cell cancer - SWOT analysis
  • Figure 82: Datamonitor Healthcare's drug assessment summary for AGS-003 in renal cell cancer
  • Figure 83: Datamonitor Healthcare's drug assessment summary for AGS-003 in renal cell cancer
  • Figure 84: Cometriq for renal cell cancer - SWOT analysis
  • Figure 85: Datamonitor Healthcare's drug assessment summary for Cometriq in renal cell cancer
  • Figure 86: Datamonitor Healthcare's drug assessment summary for Cometriq in renal cell cancer
  • Figure 87: Atezolizumab for renal cell cancer - SWOT analysis
  • Figure 88: Datamonitor Healthcare's drug assessment summary for atezolizumab in renal cell cancer
  • Figure 89: Datamonitor Healthcare's drug assessment summary for atezolizumab in renal cell cancer

List of tables

  • Table 1: RCC drug sales in the US, Japan, and five major EU markets ($m), 2013-22
  • Table 2: Renal cell cancer drug sales in the US, Japan, and five major EU markets, by brand and status ($m), 2015-24
  • Table 3: Renal cell cancer drug sales in the US, by brand and status ($m), 2015-24
  • Table 4: Renal cell cancer drug sales in Japan, by brand and status ($m), 2015-24
  • Table 5: Renal cell cancer drug sales in the five major EU markets, by brand and status ($m), 2015-24
  • Table 6: Summary of drug classes and molecules in Datamonitor Healthcare's RCC patient-based forecast
  • Table 7: Exchange rates used for calculating prices
  • Table 8: Patent expiry dates for key marketed brands in renal cell cancer in the US, Japan, and five major EU markets
  • Table 9: Datamonitor Healthcare's estimated launch dates of key late-stage pipeline products and marketed brands in renal cell cancer
  • Table 10: Afinitor sales for RCC in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 11: Afinitor patient numbers for RCC in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 12: AGS-003 sales for RCC in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 13: AGS-003 patient numbers for RCC in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 14: Atezolizumab sales for RCC in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 15: Atezolizumab patient numbers for RCC in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 16: Avastin sales for RCC in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 17: Avastin patient numbers for RCC in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 18: Cometriq sales for RCC in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 19: Cometriq patient numbers for RCC in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 20: Inlyta sales for RCC in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 21: Inlyta patient numbers for RCC in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 22: Lenvima sales for RCC in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 23: Lenvima patient numbers for RCC in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 24: Nexavar sales for RCC in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 25: Nexavar patient numbers for RCC in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 26: Opdivo sales for RCC in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 27: Opdivo patient numbers for RCC in the US, Japan, and five major EU markets, by country,2015-24
  • Table 28: Sutent sales for RCC in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 29: Sutent patient numbers for RCC in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 30: Torisel sales for RCC in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 31: Torisel patient numbers for RCC in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 32: Votrient sales for RCC in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 33: Votrient patient numbers for RCC in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 34: Oncologists and urologists surveyed for the renal cell cancer primary research study, 2015
  • Table 35: Oncologists and urologists surveyed for the renal cell cancer primary research study, 2015
  • Table 36: Renal cell cancer five-year survival rates, by stage at diagnosis, 2005-11
  • Table 37: Leading treatments for renal cell cancer
  • Table 38: Cancer registries used in the analysis
  • Table 39: Diagnosed incident cases of renal cell carcinoma in the US, Japan, and five major EU markets, by country, 2014-34
  • Table 40: Age-specific diagnosed incident cases of renal cell carcinoma in the US, Japan, and five major EU markets, by country, 2014
  • Table 41: Gender-specific diagnosed incident cases of renal cell carcinoma in the US, Japan, and five major EU markets, by country, 2014
  • Table 42: Diagnosed incident cases of renal cell carcinoma by stage at diagnosis in the US, Japan, and five major EU markets, by country, 2014
  • Table 43: Diagnosed prevalent cases of renal cell carcinoma in the US, Japan, and five major EU markets, by country, 2014-34
  • Table 44: Key marketed drugs for renal cell cancer
  • Table 45: Afinitor drug profile
  • Table 46: Afinitor pivotal trial data in renal cell cancer
  • Table 47: Avastin drug profile
  • Table 48: Avastin pivotal trial data in renal cell cancer
  • Table 49: Inlyta drug profile
  • Table 50: Inlyta pivotal trial data in renal cell cancer
  • Table 51: Nexavar drug profile
  • Table 52: Nexavar pivotal trial data in renal cell cancer
  • Table 53: Opdivo drug profile
  • Table 54: Opdivo ongoing late-phase clinical trials in renal cell cancer
  • Table 55: Sutent drug profile
  • Table 56: Overview of pivotal trial data for Sutent in renal cell cancer
  • Table 57: Sutent ongoing late-phase clinical trials in renal cell cancer
  • Table 58: Torisel drug profile
  • Table 59: Torisel pivotal trial data in renal cell cancer
  • Table 60: Votrient drug profile
  • Table 61: Votrient pivotal trial data in renal cell cancer
  • Table 62: Votrient late-phase trial data in renal cell cancer
  • Table 63: Votrient ongoing late-phase clinical trials in renal cell cancer
  • Table 64: Phase III pipeline products in development for renal cell cancer
  • Table 65: Late-stage compounds that were recently discontinued for renal cell cancer
  • Table 66: Sutent drug profile
  • Table 67: Typical Phase III clinical trial design in renal cell cancer
  • Table 68: Clinical endpoints that led to the approval of current treatments for renal cell cancer
  • Table 69: AGS-003 drug profile
  • Table 70: AGS-003 Phase III trials in renal cell cancer
  • Table 71: AGS-003 Phase II data in renal cell cancer
  • Table 72: Cometriq drug profile
  • Table 73: Cometriq Phase III trials in renal cell cancer
  • Table 74: Atezolizumab drug profile
  • Table 75: Atezolizumab Phase III trials in renal cell cancer
  • Table 76: Summary of therapeutic classes in renal cell cancer by ATC code
Back to Top